Effect of Valerian on Anxiety and Quality of Life in Patients with Type 1 Diabetes
Phase 3
- Conditions
- Anxiety.Generalized anxiety disorder
- Registration Number
- IRCT20181126041754N1
- Lead Sponsor
- Sanandaj University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 92
Inclusion Criteria
Patients with type 1 diabetes
Age of 14-18 years
Ensure full vigilance
Have reading and writing skills
Ability to communicate
Satisfaction to participate in the study
Have a lasting diagnosis of diabetes for at least a year
Not having a history of liver and kidney disease
Not having a history of mental illness
Exclusion Criteria
Use of any hypnotic and analgesic drug
drug allergy
Pregnancy and lactation
Taking heparin by the patient
Unwilling to participate in the study
being admitted to the hospital
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Anxiety Score in Beck's Inventory. Timepoint: Befor the intervention, four weeks after the intervention, eight weeks after the intervention. Method of measurement: Beck Anxiety Inventory.
- Secondary Outcome Measures
Name Time Method Quality of Life Score. Timepoint: Before the intervention, eight weeks after the intervention. Method of measurement: Thomas and Associates Quality of Life Questionnaire.